All Stories

  1. An Analysis of Japanese Patients Enrolled in Multiregional Clinical Trials in Oncology

    Article • Therapeutic Innovation & Regulatory Science, March 2017, SAGE Publications

    Dr Akihiro Hirakawa

  2. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data

    Article • Statistics in Medicine, February 2017, Wiley

    Dr Akihiro Hirakawa

  3. Drug induced interstitial lung disease in oncology phase I trials

    Article • Cancer Science, December 2016, Wiley

    Dr Akihiro Hirakawa

  4. Effect of design specifications in dose-finding trials for combination therapies in oncology

    Article • Pharmaceutical Statistics, August 2016, Wiley

    Dr Akihiro Hirakawa

  5. Authors' Reply

    Article • Statistics in Medicine, January 2016, Wiley

    Dr Akihiro Hirakawa

  6. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study

    Article • Breast Cancer, October 2015, Springer Science + Business Media

    Dr Akihiro Hirakawa

  7. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?

    Article • Lung Cancer, July 2015, Elsevier

    Dr Akihiro Hirakawa

  8. A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study

    Article • Neuromuscular Disorders, July 2015, Elsevier

    Dr Akihiro Hirakawa

  9. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group

    Article • International Journal of Clinical Oncology, June 2015, Springer Science + Business Media

    Dr Akihiro Hirakawa

  10. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies

    Article • Statistics in Medicine, May 2015, Wiley

    Dr Akihiro Hirakawa

  11. Valve Selection for the Aortic Position in Dialysis Patients

    Article • The Annals of Thoracic Surgery, May 2015, Elsevier

    Dr Akihiro Hirakawa

  12. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma

    Article • The Japanese Journal of Thoracic and Cardiovascular Surgery, February 2015, Springer Science + Business Media

    Dr Akihiro Hirakawa

  13. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies

    Article • Clinica Chimica Acta, February 2015, Elsevier

    Dr Akihiro Hirakawa

  14. Enhancing the Lasso Approach for Developing a Survival Prediction Model Based on Gene Expression Data

    Article • Computational and Mathematical Methods in Medicine, January 2015, Hindawi Publishing Corporation

    Dr Akihiro Hirakawa

  15. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus

    Article • Endocrine Journal, January 2015, Japan Endocrine Society

    Dr Akihiro Hirakawa

  16. Administration of Umbilical Cord Blood Cells Transiently Decreased Hypoxic-Ischemic Brain Injury in Neonatal Rats

    Article • Developmental Neuroscience, January 2015, Karger Publishers

    Dr Akihiro Hirakawa, MD, PhD Klas Blomgren

  17. Operating Characteristics of Restrictions on Skipping Dose Level for Adaptive Dose-Finding Method in Two-Agent Phase I Trials

    Article • Japanese Journal of Biometrics, January 2015, The Biometric Society of Japan

    Dr Akihiro Hirakawa

  18. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, December 2014, Taylor & Francis

    Dr Akihiro Hirakawa

  19. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials

    Article • Journal of Biopharmaceutical Statistics, November 2014, Taylor & Francis

    Dr Akihiro Hirakawa

  20. A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan

    Article • Current Drug Safety, September 2014, Bentham Science Publishers

    Dr Akihiro Hirakawa

  21. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer

    Article • Interactive Cardiovascular and Thoracic Surgery, July 2014, Oxford University Press (OUP)

    Dr Akihiro Hirakawa

  22. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data

    Article • Pharmaceutical Statistics, July 2014, Wiley

    Dr Akihiro Hirakawa

  23. Response to letter to the editor by Dr Wages et al.

    Article • Statistics in Medicine, May 2014, Wiley

    Dr Akihiro Hirakawa

  24. Reply to: Appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer

    Article • Surgery, May 2014, Elsevier

    Dr Akihiro Hirakawa

  25. Bayesian Model Averaging Continual Reassessment Method for Bivariate Binary Efficacy and Toxicity Outcomes in Phase I Oncology Trials

    Article • Journal of Biopharmaceutical Statistics, March 2014, Taylor & Francis

    Dr Akihiro Hirakawa

  26. Dose-Finding Methods for Two-Agent Combination Phase I Trials

    Article • January 2014, Springer Science + Business Media

    Dr Akihiro Hirakawa

  27. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan

    Article • Journal of Gynecologic Oncology, January 2014, Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

    Dr Akihiro Hirakawa

  28. Overview of Model-Based Dose-Finding Methods for Combinations of Two Agents in Phase I Oncology Trials

    Article • Japanese Journal of Biometrics, January 2014, The Biometric Society of Japan

    Dr Akihiro Hirakawa

  29. Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component: Modified Clinical T Descriptors of the Tumor, Node, Metastasis Classification of Lung Cancer

    Article • Journal of Thoracic Oncology, December 2013, Elsevier

    Dr Akihiro Hirakawa

  30. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients

    Article • International Journal of Urology, August 2013, Wiley

    Dr Akihiro Hirakawa

  31. Ablation of Keratan Sulfate Accelerates Early Phase Pathogenesis of ALS

    Article • PLoS ONE, June 2013, PLOS

    Dr Akihiro Hirakawa

  32. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials

    Article • Statistics in Medicine, May 2013, Wiley

    Dr Akihiro Hirakawa

  33. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates

    Article • Acta Paediatrica, April 2013, Wiley

    Dr Akihiro Hirakawa

  34. A Stepwise Variable Selection for a Cox Proportional Hazards Cure Model with Application to Breast Cancer Data

    Article • Japanese Journal of Biometrics, January 2013, The Biometric Society of Japan

    Dr Akihiro Hirakawa

  35. Use of Cox’s Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response

    Article • International Journal of Breast Cancer, January 2013, Hindawi Publishing Corporation

    Dr Akihiro Hirakawa

  36. Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal

    Article • PLoS ONE, August 2012, PLOS

    Dr Akihiro Hirakawa

  37. An Analysis of Guidance for Proper Usage Documents for Oncology Drugs in Japan

    Article • Pharmaceutical Medicine, June 2012, Springer Science + Business Media

    Dr Akihiro Hirakawa

  38. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy

    Article • Journal of Cancer Research and Clinical Oncology, March 2012, Springer Science + Business Media

    Dr Akihiro Hirakawa

  39. Gene Selection using a High-Dimensional Regression Model with Microarrays in Cancer Prognostic Studies

    Article • Cancer Informatics, February 2012, Libertas Academica, Ltd.

    Dr Akihiro Hirakawa

  40. Immunohistochemical Profile for Unknown Primary Adenocarcinoma

    Article • PLoS ONE, January 2012, PLOS

    Dr Akihiro Hirakawa

  41. Sample Size Calculation Through the Incorporation of Heteroscedasticity and Dependence for a Penalizedt-Statistic in Microarray Experiments

    Article • Journal of Biopharmaceutical Statistics, January 2012, Taylor & Francis

    Dr Akihiro Hirakawa

  42. Significant Association between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer

    Article • Biological and Pharmaceutical Bulletin, January 2012, Pharmaceutical Society of Japan

    Dr Akihiro Hirakawa

  43. Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, December 2011, Elsevier

    Dr Akihiro Hirakawa

  44. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials

    Article • Statistics in Medicine, November 2011, Wiley

    Dr Akihiro Hirakawa

  45. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

    Article • International Journal of Clinical Oncology, November 2011, Springer Science + Business Media

    Dr Akihiro Hirakawa

  46. Sample size calculation for a regularized -statistic in microarray experiments

    Article • Statistics & Probability Letters, July 2011, Elsevier

    Dr Akihiro Hirakawa

  47. Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma

    Article • Annals of Surgical Oncology, March 2011, Springer Science + Business Media

    Dr Akihiro Hirakawa

  48. Adaptive clinical trials for new drug applications in Japan

    Article • European Neuropsychopharmacology, February 2011, Elsevier

    Dr Akihiro Hirakawa

  49. The notorious “drug lag” for oncology drugs in Japan

    Article • Investigational New Drugs, February 2011, Springer Science + Business Media

    Dr Akihiro Hirakawa

  50. Do investigators show selection biases when enrolling patients in phase I oncology registration trials?

    Article • Journal of Geriatric Oncology, January 2011, Elsevier

    Dr Akihiro Hirakawa

  51. Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”

    Article • Statistics in Biopharmaceutical Research, November 2010, Taylor & Francis

    Dr Akihiro Hirakawa

  52. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer

    Article • Cancer Immunology Immunotherapy, March 2010, Springer Science + Business Media

    Dr Akihiro Hirakawa

  53. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

    Article • Journal of Surgical Oncology, January 2010, Wiley

    Dr Akihiro Hirakawa

  54. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but notHER2/neu-positive breast cancer

    Article • Cancer, January 2010, Wiley

    Dr Akihiro Hirakawa

  55. Influence of Suboptimal Treatment in Patients with Mediastinal Primary Nonseminomatous Germ Cell Tumors

    Article • Oncology, January 2010, Karger Publishers

    Dr Akihiro Hirakawa